Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aptorum Group Ltd APM

Healthcare Biotechnology
Aptorum Group Limited is a United Kingdom-based clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a novel molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore's Agency for Science, Technology and Research.


NDAQ:APM - Post by User

Aptorum Group Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(247)
•••
Post by whytestockson Mar 06, 2024 11:30am
32 Views
Post# 35918156

Aptorum Group Plans of Merge with YOOV Group Holding and a S

Aptorum Group Plans of Merge with YOOV Group Holding and a S
JUST IN: $APM Aptorum Group Plans of Merge with YOOV Group Holding and a Split-off its Legacy Business2024-03-06 09:53:06 ET DENVER, Colo., Mar 06, 2024 ( 247marketnews.com )- Aptorum Group Limited (NASDAQ: APM ) announced, jointly with privately-held YOOV Group Holding Ltd., this morning, that the two companies entered into an Agreement and Plan of Merger, which still needs shareho...APM - Aptorum Group Plans of Merge with YOOV Group Holding and a Split-off its Legacy Business

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities